Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC)

Documenti analoghi

• Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia (R/R AML)
  di: Dinardo, CD, et al.
  Pubblicazione: (2022)
• Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
  di: DiNardo, CD, et al.
  Pubblicazione: (2021)
• Molecular features associated with response to enasidenib plus azacitidine in newly diagnosed IDH2-mutated acute myeloid leukemia
  di: Risueño, A, et al.
  Pubblicazione: (2023)
• Outcomes for patients with late-stage mutant-IDH2 (m IDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the randomized, phase 3 IDHentify Trial
  di: DiNardo, CD, et al.
  Pubblicazione: (2021)
• Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
  di: Stein, EM, et al.
  Pubblicazione: (2017)